Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Convertible Debt: 2020-2024

Historic Convertible Debt for Collegium Pharmaceutical (COLL) over the last 5 years, with Dec 2024 value amounting to $237.2 million.

  • Collegium Pharmaceutical's Convertible Debt rose 0.44% to $237.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.9 million, marking a year-over-year increase of 0.44%. This contributed to the annual value of $237.2 million for FY2024, which is 9.52% down from last year.
  • According to the latest figures from FY2024, Collegium Pharmaceutical's Convertible Debt is $237.2 million, which was down 9.52% from $262.1 million recorded in FY2023.
  • Collegium Pharmaceutical's 5-year Convertible Debt high stood at $262.1 million for FY2023, and its period low was $39.5 million during FY2020.
  • Moreover, its 3-year median value for Convertible Debt was $237.2 million (2024), whereas its average is $213.4 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Convertible Debt surged by 254.44% in 2021 and then decreased by 9.52% in 2024.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's Convertible Debt stood at $39.5 million in 2020, then soared by 254.44% to $140.0 million in 2021, then grew by 0.65% to $140.9 million in 2022, then soared by 86.07% to $262.1 million in 2023, then dropped by 9.52% to $237.2 million in 2024.